

IKK α , active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-461, 14-461-K, 14-461M

Parent Lot # WAA0185

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal GST-tagged recombinant, full-length human IKK α expressed by baculovirus in Sf21 insect cells. Purified using glutathione agarose. Purity 89.8% by SDS-PAGE and Coomassie blue staining. MW = 112kDa.

Specific Activity (Parent lot# WAA0185): 106U/mg, where one unit of IKK α , active activity is defined as 1nmol phosphate incorporated into 200 μ M (KKKKERLLDDRHSGLDSMKDEE) per minute at 30°C with a final ATP concentration of 100 μ M.

Formulation: 0.253mg/ml of enzyme in 50mM Tris/HCl pH7.5, 150mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
 NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 5–105ng of this lot of enzyme phosphorylated 200 μ M (KKKKERLLDDRHSGLDSMKDEE) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as IKK α with the translated native sequence listed on page three.



Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS-NaOH pH7.0, 1mM EDTA.
2. **(KKKKERLLDDRHDSGLDSMKDEE):** Use at a final assay concentration of 200µM. Prepare a 1mM stock and add 5µl of stock to each assay point.
3. **IKKα active:** Dilute with 20mM MOPS-NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 5–105ng per assay point.
4. **[γ-³³P]ATP:** 2.5 x magnesium acetate/[γ-³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ-³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 5µl of 5 x reaction buffer per assay to wells.
2. Add 5µl of (KKKKERLLDDRHDSGLDSMKDEE).
3. Add 2.5µl (5–105ng) IKKα, active.
4. Add 2.5µl of dH₂O.
5. Add 10µl of diluted [γ-³³P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5µl of 3% phosphoric acid.
8. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

IKK α Sequence Information

Protein	human IKK α
Tags	N-terminal GST
Native sequence	M231 of the recombinant protein is equivalent to M1 of human IKK α
Accession number	GenBank AF012890

Recombinant IKK α amino acid sequence:

```

1 MSPILGYWKI KGLVQPTRL L LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID
61 GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV
121 DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK
181 KRIEAIQID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD LEVLFQGPFE MERPPGLRPG
241 AGGPWEMRER LGTGGFGNVC LYQHRELDL IAIKSCRLEL STKNRERWCH EIQIMKKLNH
301 ANVVKACDVP EELNILIHDV PLLAMEYCSG GDLRKLLNKP ENCCGLKESQ ILSLLSDIGS
361 GIRYLHENKI IHRDLKPENI VLQDVGGKII HKIIDLGYAK DVDQGSLSCTS FVGTLQYLAP
421 ELFENKPYTA TVDYWSFGTM VFECIAGYRP FLHHLQPFTW HEKIKKKDPK CIFACEEMSG
481 EVRFSSHLPQ PNSLCSLIVE PMENWLQLML NWDPQQRGGP VDLTLKQPRC FVLMDHILNL
541 KIVHILNMTS AKIISFLLPP DESLHSLQSR IERETGINTG SQELLSETGI SLDPRKPASQ
601 CVLDGVRGCD SYMVYLFDKS KTVYEGPFAS RSLSDCVNYI VQDSKIQLPI IQLRKVWAEA
661 VHYVSGLKED YSRLFQGQRA AMLSLLRYNA NLTKMKNTLI SASQQLKAKL EFFHKSIQLD
721 LERYSEQMTY GISSEKMLKA WKEMEKAH YAEVGVIGYL EDQIMSLHAE IMELQKSPYG
781 RRQGDLMESL EQRAIDLYKQ LKHRPSDHSY SDSTEMVKII VHTVQSQDRV LKELFGHLSK
841 LLGCKQKIID LLPKVEVALS NIKEADNTVM FMQGRQKEI WHLLKIACTQ SSARSLVGSS
901 LEGAVTPQTS AWPPTS AEH DHSLSCVVTP QDGETSAQMI EENLNCLGHL STIIHEANEE
961 QGNSMMNLDW SWLTE

```

Recombinant IKK α nucleotide sequence:

```

\      1 atgtccccta tactagggtta ttggaaaatt aagggccttg tgcaaccac tcgacttctt
61 ttggaatatc ttgaagaaaa atatgaagag catttgtagt agcgcatga aggtgataaa
121 tggcgaaaca aaaagttaga attgggttg gagtttccca atcttcctta ttatattgat
181 ggtgatgtta aattaacaca gtctatggcc atcatagctt atatatagct caagcacaa
241 atgttggttg gttgtccaaa agagcgtgca gagatttcaa tgcttgaagg agcggttttg
301 gatattagat acggtgtttc gagaattgca tatagtaaag actttgaaac tctcaaagtt
361 gattttctta gcaagctacc tgaaatgctg aaaatgttcg aagatcgttt atgtcataaa
421 acatatatta atggtgatca tgtaaccat cctgacttca tgttgtagta cgctcttgat
481 gttgttttat acatggacc aatgtgcctg gatgcgttcc caaaattagt ttgttttaaa
541 aaacgtattg aagctatccc acaaattgat aagtacttga aatccagcaa gtatatagca
601 tggcctttgc agggctggca agccacgtt ggtggtggcg accatcctcc aaaatcggat
661 ctggaagtgc tgttcagggg gccgaattc atggagcggc ccccggggct gcggccgggc
721 gcgggcgggc cctgggagat gcgggagcgg ctgggcaccg gcggcttcgg gaacgtctgt
781 ctgtaccagc atcgggaact tgatctcaaa atagcaatta agtcttctgc cctagagcta
841 agtaccaaaa acagagaacg atggtgccat gaaatccaga ttatgaagaa gttgaaccat
901 gccaatgttg taaaggcctg tgatgttcct gaagaattga atattttgat tcatgatgtg
961 cctcttctag caatggaata ctgttctgga ggagatctcc gaaagctgct caacaaacca
1021 gaaaattggt gtggacttaa agaaagccag atactttctt tactaagtga tatagggtct
1081 gggattcgat atttgcataa aaacaaaatt atacatcgag atctaaaacc tgaacata
1141 gttcttcagg atgttggtgg aaagataata cataaaataa ttgatctggg atatgcaaaa
1201 gatgttgatc aagggaagtct gtgtacatct tttgtgggaa cactgcagta tctggcccca
1261 gagctctttg agaataagcc ttacacagcc actgttgatt attggagctt tgggaccatg
1321 gtatttgaat gtattgctgg atataggcct tttttgcata atctgcagcc atttacctgg
1381 catgagaaga ttaagaagaa ggatccaaag tgtatatttg catgtgaaga gatgtcagga

```

Certificate of Analysis

```

1441 gaagttcggg ttagtagcca ttacacctcaa ccaaatagcc tttgtagttt aatagtagaa
1501 cccatggaaa actggctaca gttgatgttg aattgggacc ctacagcagag aggaggacct
1561 gttgacctta ctttgaagca gccaaagatgt tttgtattaa tggatcacat tttgaatttg
1621 aagatagtac acatcctaaa tatgacttct gcaaagataa tttcttttct gttaccacct
1681 gatgaaagtc ttcattcact acagtctcgt attgagcgtg aaactggaat aaatactggt
1741 tctcaagaac tcttttcaga gacaggaatt tctctggatc ctcggaacc agcctctcaa
1801 tgtgttctag atggagtttag aggctgtgat agctatatgg tttatttggt tgataaaagt
1861 aaaactgtat atgaagggcc atttgcttcc agaagtttat ctgattgtgt aaattatatt
1921 gtacaggaca gcaaaatata gcttccaatt atacagctgc gtaaaagtgt ggctgaagca
1981 gtgcactatg tgtctggact aaaagaagac tatagcaggc tctttcaggg acaaagggca
2041 gcaatgttaa gtcttcttag atataatgct aacttaacaa aaatgaagaa cactttgatc
2101 tcagcatcac aacaactgaa agctaaattg gagttttttc acaaaagcat tcagcttgac
2161 ttggagagat acagcgagca gatgacgtat gggatatctt cagaaaaaat gctaaaagca
2221 tggaaagaaa tggaaagaaa ggccatccac tatgctgagg ttggtgtcat tggatactg
2281 gaggatcaga ttatgtcttt gcatgctgaa atcatggagc tacagaagag cccctatgga
2341 agacgtcagg gagacttgat ggaatctctg gaacagcgtg ccattgatct atataagcag
2401 ttaaaacaca gaccttcaga tcactcctac agtgacagca cagagatggt gaaaatcatt
2461 gtgcacactg tgcagagtca ggaccgtgtg ctcaaggagc tgttttgtca tttgagcaag
2521 ttgttgggct gtaagcagaa gattattgat ctactcccta aggtggaagt ggccctcagt
2581 aatatcaaag aagctgacaa tactgtcatg ttcatgcagg gaaaaaggca gaaagaaata
2641 tggcatctcc ttaaaattgc ctgtacacag agttctgccc ggtcccttgt aggatccagt
2701 ctagaagggtg cagtaacccc tcagacatca gcatggctgc cccgacttc agcagaacat
2761 gatcattctc tgtcatgtgt ggtaactcct caagatgggg agacttcagc acaaatgata
2821 gaagaaaatt tgaactgcct tggccattta agcactatta ttcatgaggc aaatgaggaa
2881 cagggcaata gtatgatgaa tcttgattgg agttgggttaa cagaatga

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services